1 / 2

R3Mab Treatment Reduces Human pro-MMP-10 in RT112 and UMUC-14 Xenograft Tumor Models

The study investigates the effects of R3Mab on serum levels of human pro-MMP-10 in mice with RT112 and UMUC-14 xenograft tumors. Mice with established tumors received either a control antibody or R3Mab treatment. Serum was collected at 48 and 96 hours post-treatment, and human pro-MMP-10 levels were measured using ELISA. The results indicate that R3Mab significantly reduces pro-MMP-10 levels in a dose- and time-dependent manner, providing insights into its potential therapeutic benefits in cancer models.

indira-evans
Download Presentation

R3Mab Treatment Reduces Human pro-MMP-10 in RT112 and UMUC-14 Xenograft Tumor Models

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pro-MMP-10 (ng/mL) 48 hr 96 hr Supplemental Figure 6 R3Mab reduces serum levels of human pro-MMP-10 in mice bearing RT112 xenograft tumors in a dose- and time-dependent manner. Mice with pre-established RT112 tumors were grouped randomly into cohorts of 5 for treatment with either a control antibody (0) or R3Mab (3 or 30 mg/kg). Serum was collected at 48 hr or 96 hr post-treatment, and human pro-MMP-10 level was measured by Elisa.

  2. A B Supplemental Figure 7 R3Mab reduces serum levels of human MMP-1 and pro-MMP-10 in mice bearing UMUC-14 xenograft tumors. Mice with pre-established UMUC-14 tumors were grouped randomly into cohorts of 10 and treated with a control antibody (Ctrl Ab) or R3Mab (30 mg/kg). Serum was collected at indicated time points, and subject to ELISA for total human MMP-1 (A) and pro-MMP-10 (B).

More Related